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We report a case of multidrug-resistance (MDR) in a strain of Bacteroides fragilis from a blood
culture and abdominal fluid in a Danish patient. The patient had not been travelling for several
years and had not received antibiotics prior to the present case. We also summarize the cases
that have been reported to date of MDR B. fragilis group in Europe. As far as we know, a case like
this with MDR B. fragilis has not been described in Scandinavia before.
Introduction
Bacteroides fragilis group strains are important opportunistic
pathogens and the most frequently isolated anaerobic
bacteria from patients with intra-abdominal infections,
deep tissue infections, abscesses and bacteraemia (Lo¨fmark
et al., 2010; Nagy, 2010). It is known that recently there has
been an increase in resistance to antibiotics commonly used
for anaerobic bacteria (Nagy et al., 2011), and also an
increase in resistance to carbapenems, and in some cases to
metronidazole. Recently, two studies have demonstrated
that alarming numbers of B. fragilis group isolates harbour
the cfiA gene, with 27 % of Bacteroides species from a
Turkish university hospital and 7.4 % of B. fragilis isolates
from a Belgian multi-centre survey possessing cfiA (Toprak
et al., 2012; Wybo et al., 2011). Although the presence of the
cfiA gene does not equate to resistance to carbapenems, this
development is of some concern.
Case report
An 84-year-old male was diagnosed with colon cancer in July
2010. In September 2010 he was admitted for laparoscopic
hemicolectomy. After the operation he had complications
with bleeding from several drains in his abdomen. Six days
after the operation his condition worsened, with signs of
sepsis. Antibiotic treatment with meropenem 1 g three times a
day and metronidazole 500 mg three times a day was initiated,
and he was transferred to the intensive care unit (ICU).
At the ICU the patient experienced bacteraemia and
fungaemia with Enterococcus faecium, Candida glabrata
and Candida albicans; this required additional treatment
with caspofungin and vancomycin. Sixteen days after the
patient’s admission to the ICU, he had septic shock with
multiorgan failure. The following day an anaerobic Gram-
negative rod was cultured from blood. The isolate was
identified by partial 16S rDNA sequencing (MicroSeq 500
system, Perkin-Elmer, Applied Biosystems Division) as B.
fragilis. The isolate was screened by disk diffusion for
antimicrobial susceptibility, and showed very small zone
diameters for metronidazole, meropenem, piperacillin-
tazobactam and clindamycin. Antimicrobial susceptibility
was confirmed with Etest (bioMe´rieux) according to the
manufacturer’s instructions on Brucella Blood Agar supple-
mented with vitamin K and haemin (Becton Dickinson).
The plates were pre-reduced for 24 h at 37 uC in an
anaerobic chamber before use. The isolate was resistant to
metronidazole, meropenem, imipenem, clindamycin and
piperacillin/tazobactam, intermediate for tetracycline, and
susceptible to tigecycline. Antimicrobial susceptibility test
results are presented in Table 1.
The strain was positive for b-lactamase production by the
nitrocefin disk method (Cefinase; BBL, Becton Dickinson).
Resistance to carbapenems was further investigated by the
metallo-b-lactamase (MBL) imipenem double-ended Etest
strip, which detected the presence of a functional MBL by a
decrease in MIC from 48 to 1 mg l21 in the presence of
EDTA (Walsh et al., 2002). To confirm the MBL phenotype
and other mechanisms of resistance in this multidrug-
resistant (MDR) strain of B. fragilis, the isolate was sent to
the Institute of Clinical Microbiology, University of Szeged,
Szeged, Hungary, for further examination. In the isolate,
with the MBL-producing phenotype, we could detect by
PCR the well-known cfiA gene characteristic of carbape-
nem-resistant B. fragilis strains. To account for the high
carbapenem MICs, we investigated its activation by
insertion sequence (IS) elements, as described previously
(So´ki et al., 2004). In the upstream region of this cfiA gene,
nucleotide sequencing demonstrated a novel IS613-like
element, ISBf12. The sequence was submitted to GenBank
(accession no. JN801071), and its nucleotide sequence had
Abbreviations: ICU, intensive care unit; IS, insertion sequence; MBL
metallo-b-lactamase; MDR, multidrug-resistance/resistant.
The GenBank/EMBL/DDBJ accession number for the sequence of the
novel B. fragilis IS613-like element, ISBf12, discussed in this study is
JN801071.
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Table 1. Cases with MDR B. fragilis-group infection
Breakpoint is defined by European Committee on Antimicrobial Susceptibility Testing (EUAST) guidelines, except for cefoxitin (CFX), tigecycline (TIG) and tetracycline (TET), for which the
breakpoint is defined by the Clinical and Laboratory Standards Institute (CLSI). LIN, linezolid (no breakpoint available). Other abbreviations: MTZ, metronidazole; MER, meropenem; IMI,
imipenem; AMC, amoxicillin/clavulanic acid; PIP/TAZ, piperacillin/tazobactam; CLI, clindamycin; LEV, levofloxacin; FLU, fluconazole; MOX, moxifloxacin; CAS, caspofungin; VAN, vancomycin;
CFO, cefotaxime; CTX, ceftriaxone, CEF, cefuroxime; GEN, gentamicin; AMI, amikacin; AMP-B, liposomal amphotericin B; CHL, chloramphenicol; S, sensitive; I, intermediate; R, resistant; ND,
not described; M, male; F, female; GB, UK; GR, Germany; FR, France; DK, Denmark.
Patient
(age and
sex)
Isolate Clinical presentation MIC (mg ml”1) Treatment Outcome Country of
isolation and
reference
MTZ
(¡4/.4)
MER
(¡2/.8)
IMI
(¡2/.8)
AMC
(¡4/.8)
PIP/TAZ
(¡8/.16)
CFX
(¡64/.64)
CLI
(¡4/.4)
LIN
ND
TET
(¡4/.8)
TIG
(¡4/.8)
38F B. fragilis
(pus+blood)
Complication after
elective laporatomy
for vaginal-wall
adhesions and tissue
nodule
8 R ND 32 R 64 R ND ND ND ND ND ND CFO MTZ CLI
GEN
Prolonged
hospital
stay and
infection.
Resolved
GB; Turner
et al. (1995)
37M Bacteroides
distasonis
(pus)
Complication after
endoscopic
retrograde
cholangeo-
pancreatography
(ERCP),
laparoscopic
cholecystectomy and
sphincterectomy.
Known to have renal
transplant
.32 R .32 R .32 R 16 R .128 R .128 R .128 R ND ND ND Immunosuppressive
CTX AMI MTZ
MER AMP-B
Died GB; Rotimi
et al. (1999)
48F B. fragilis
(pus+blood)
Complication after
ERCP for gallstones
.256 R .256 R .32 R .256 R ND .256 R .256 R 1.0 .256 R ND CEF MTZ IMI
PIP/TAZ AMI
CHL AMP-B LIN
Died GB; Wareham
et al. (2005)
71M B. fragilis
(blood)
Diarrhoea. Known to
have Crohn’s disease
0.5 S ND .32 R ND .256 R .256 R .256 R ND 128 R ND MTZ CFO Died GR; Katsandri
et al. (2006)
75M Bacteroides
vulgatus (pus)
Complication after
surgical procedure
due to gastric
carcinoma
.256 R ND .32 R ND .256 R .256 R .256 R ND .256 R ND LEV PIP/TAZ FLU
IMI
Died GR; Katsandri
et al. (2006)
ND B. fragilis
(wound)
ND 16 R ND .32 R 4 S 4 S .256 R 0.125 S ND ND 0.1 S ND ND FR; Nagy
et al. (2011)
84M B. fragilis
(pus+blood)
Complication after
elective laparoscopic
hemicolectomy due
to colon cancer
16 R .32 R 16 R ND .256 R ND 6 R ND 8 I 1.5 S MER MTZ CAS VAN Died 2012 DK; this
study
M
ultidrug
-resistan
t
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92 % homology to IS613 (Kato et al., 2003), 92 % homology
to the IS element upstream of the cfiA gene of B. fragilis
YMC00/6/496 (Roh et al., 2010), and 76 % homology (not
including the rightmost approximately 100 nt) to IS614
(Kato et al., 2003) and IS614B (So´ki et al., 2004). The strain
harboured 2.7, 4.2 and 7.3 kb plasmids. The cfiA gene could
not be detected on these plasmids by Southern hybridiza-
tion, so its location was chromosomal, as is usually the case
for cfiA genes. The analysis of the metronidazole resistance
mechanism was done by PCR sequencing and Southern
blotting (So´ki et al., 2006), and revealed a nim plasmid,
pIP421 (Trinh et al., 1995), in this strain by examination of
molecular size (7.3 kb), nim gene type (nimD), the IS
element activating this nimD gene (IS1169), and Southern
blotting of its EcoRI and EcoRV restriction fragments.
Further molecular analysis detected the ermF, tetQ and tetX
variant resistance genes in this strain (Bartha et al., 2011).
ermF may mediate the strain’s clindamycin resistance, and
tetQ its reduced susceptibility to tetracycline; however, the
strain was still susceptible to tigecycline (Bartha et al., 2011).
The ICU was recommended to change antibiotics to
tigecycline for optimal treatment of the patient and his
infection, but because the patient was apparently improv-
ing, there was no change in treatment. On day 25 after the
patient was admitted to hospital, he suffered a new event of
septic shock and died.
Blood cultures taken 3 days after the first blood culture and
abdominal fluid from the day before the patient died
showed growth of an identical B. fragilis strain with the
same pattern of resistance.
Meropenem was administered from day 6 after his
operation to his death, and metronidazole was adminis-
tered from day 6 after his operation to day 18 and then
again from day 22 to his death.
Discussion
Anaerobic infections are often treated empirically, based on
surveillance reports of susceptibility patterns of these
pathogens (Lo¨fmark et al., 2010; Nagy, 2010; Nagy et al.,
2011; Seifert et al., 2010). Susceptibility varies considerably
among the different species in the group (Nagy, 2010; Seifert
et al., 2010). Routine identification to the species level and
determination of antimicrobial susceptibility vary between
countries and laboratories (Nagy, 2010; Nagy et al., 2011),
but optimal empirical therapy with appropriate antibiotics
has been shown to be important for favourable clinical
outcome in B. fragilis group bacteraemia. Insufficient
treatment is associated with increased mortality rates and
increased length of hospital stay (So´ki et al., 2004, 2006;
Nagy, 2010; Nguyen et al., 2000; Dubreuil & Odou, 2010).
In a Europe-wide study (Nagy et al., 2011) involving 13
countries, between January 2008 and March 2009, the
susceptibility of 824 B. fragilis group isolates against nine
antibiotics was determined. Increasing resistance was
observed for cefoxitin, clindamycin and moxifloxacin. The
lowest levels of resistance were observed for imipenem,
metronidazole (,1 %) and tigecycline. Differences were
detected between geographical areas and hospitals. Similar
studies have been performed in the USA (Snydman et al.,
2011), and they demonstrate a similar trend.
Historically, Denmark has had a low consumption of
antibiotics compared with other European countries. How-
ever, this has changed during the last decade, and
consumption of antibiotics is now higher than in other
Scandinavian countries, according to the latest report from
the European Centre for Disease Prevention and Control
(ECDC; http://www.ecdc.europa.eu/en/eaad/Documents/EA
AD-2011-Summary-Antimicrobial-Consumption-data.pdf).
Resistance to carbapenems is mostly related to one enzyme,
the cfiA MBL, Ambler class B. For the expression of this
gene, special IS elements are needed upstream of cfiA to act
as a promoter (Nagy, 2010; Toprak et al., 2012). However,
in the study of Wybo et al., 2011, it was found that the cfiA-
positive isolates had higher meropenem MICs than cfiA-
negative B. fragilis isolates, although the cfiA gene was not
activated. In our study the cfiA gene was not sequenced.
Sequencing studies of cfiA genes show that there are
molecular variants of this enzyme (Garcı´a et al., 2009;
Toprak et al., 2012), although for the high enzymic
activities required for high carbapenemase production the
role of the activating IS elements is crucial, as several
previous studies have demonstrated (Podglajen et al., 1992,
1994; Kato et al., 2003; So´ki et al., 2004; Garcı´a et al., 2009;
Toprak et al., 2012). The activating IS element, ISBf12, in
our strain was novel, but belonged to the group defined by
IS613, IS614 and IS614B. The members of this group are
often mosaics of other group members, as proposed
previously (So´ki et al., 2004), and in our case ISBf12 also
displayed a similar phenomenon. The whole IS, including
the rightmost portion, was clearly homologous to IS613,
but with respect to IS614 and IS614B, the rightmost
portion was not. The mechanisms of resistance to
tetracyclines are based on ribosomal protection. The tetQ
gene encodes a ribosomal protection protein that is
responsible for most tetracycline resistance observed in
Bacteroides strains. The tetX gene encodes an FAD- and
NADPH-requiring oxidoreductase that inactivates tetracy-
cline in the presence of oxygen (Bartha et al., 2011).
Tigecycline is a glycylcycline, a semi-synthetic derivative of
minocycline, and some data suggest that in most cases
tigecycline overcomes tetracycline resistance mechanisms
(Bartha et al., 2011), as in our case. Clindamycin resistance,
in Bacteroides strains, is mostly mediated by a macrolide-
lincomycin-streptogramin (MLS) mechanism, and the gene
encoding this type of resistance is ermF (Nagy et al., 2001).
Several metronidazole resistance mechanisms have been
described (Steffens et al., 2010), and are most commonly
expressed by the resistance gene linked to specific nitroimi-
dazole (nim) genes, named nimA–G, which are located on
the chromosome or on a plasmid (So´ki et al., 2006; Nagy,
2010; Dubreuil & Odou, 2010; Pumbwe et al., 2007).
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Metronidazole-resistant strains of the B. fragilis group have
been described in several countries, but in general, resistance
is low. In the study of Toprak et al. (2012), none of the
strains showed reduced susceptibility to metronidazole or
expressed the nim gene. As routine susceptibility testing of
anaerobic bacteria in most laboratories is only performed
from blood or other serious infections, it is difficult to
estimate how frequent MDR B. fragilis group strains are
from other sites of infection or in the colon. However, it has
been noted in the Europe-wide study of Nagy et al. (2011)
that ‘Nonsusceptible strains to imipenem and metronidazole
were more resistant to other anti-anaerobic drugs’. A few
isolates exhibiting MDR to at least two antimicrobial classes,
together with metronidazole and/or carbapenem resistance,
have been described before in Europe (Table 1). As we do
not have the full molecular profiles from these other cases,
reported in Table 1, of MDR B. fragilis group strains, it is not
possible to identify a particular gene complex or plasmid
which could be responsible for or contribute to MDR in
these strains.
In the study of Katsandri et al. (2006), it was shown in the
first case described that the strain was metronidazole-
susceptible but imipenem-resistant, and the authors detected
a cfiA gene, which is associated with carbapenem resistance.
There was no further description and no information about
IS elements. In the second case described, the authors were
not able to detect a nim gene, even though the MIC for
metronidazole was high (.256 mg l21), indicating that there
are other mechanisms, e.g. overexpression of efflux pumps,
which could explain the high MIC (Lo¨fmark et al., 2010).
The cfiA gene was also detected but not described further,
and there was no information about IS elements. In the rest
of the cases no molecular information was presented. As
already described, resistance to metronidazole is associated
with nim genes, and high metronidazole MICs are seen in
strains with plasmid and chromosomal nim genes (So´ki et al.,
2006). Some studies have shown that nimA is the most
prevalent of the nim genes (Lo¨fmark et al., 2005; Stubbs et al.,
2000). It has also been shown that the chromosomal nim
genes are often associated with the presence of the cfiA gene
(So´ki et al., 2006). All in all, these findings indicate that the
resistance mechanisms for MDR B. fragilis group strains are
complex, and we still do not know to what degree transfer of
resistance genes, including MDR, occurs between members
of the B. fragilis group.
In our case, it is difficult to determine whether the patient
died from, or with, his MDR B. fragilis strain. He had a
serious underlying condition with complications, although
apparently the colon cancer had been removed. However,
the MDR B. fragilis strain was not treated sufficiently and it
was possible to retrieve the strain on later occasions from
blood cultures and abdominal fluid.
With this report, we would like to increase awareness of
the fact that resistance is increasing in Europe against
antibiotics commonly used for anaerobic bacteria, and also
against carbapenems and metronidazole, while the frequent
presence of the cfiA gene, with the potential for a dramatic
increase in carbapenem resistance, is concerning. Decreased
susceptibility or resistance can be responsible for clinical
failures, and in cases with serious anaerobic infections it is
important to improve both the bacteriological identification
and the susceptibility testing of the antibiotics used for
therapy. It is therefore of great importance to do routine
antimicrobial susceptibility testing and not rely only on
periodically published surveillance reports in cases of serious
anaerobic infections.
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